Shares of Regeneron Pharmaceuticals, Inc. (REGN) have moved up 14.8% over the last 30 days.
All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.
But who would have thought at the results of a heart disease study could potentially provide an unexpected financial benefit to those patients with juvenile arthritis.
Novartis AG (NVS) announced top-line results from the global phase III study, CANTOS on cardiovascular drug.
This morning, Novartis, the Swiss drug giant, announced that a drug that targets inflammation prevented heart attacks and strokes. It could be a scientific breakthrough, and a commercial one, too.
Ligand Pharmaceuticals Incorporated (LGND) announced receipt of a milestone payment of $1.5 million after its partner Melinta Therapeutics' pipeline candidate Baxdela (delafloxacin) was approved by the FDA.
Novartis (NVS) announced that the EMA accepted its application for migraine candidate AMG 334.
Health Canada granted a Notice of Compliance (NOC) for Vemlidy 25mg tablets, a once-daily treatment for adults with chronic HBV infection with compensated liver disease.
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.
Amgen Inc. (AMGN) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) to expand the label of its key drug, Xgeva.
Novartis AG (NVS) announced that its generic arm, Sandoz, has received European Commission (EC) approval for Rixathon.
Here is a look at Puma (PBYI) and two other biotech stocks that have recorded massive gains so far in 2017.
Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.